Teva Pharmaceutical Industries Limited (TEVA) Key Metrics
TEVA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $48.40B
- Enterprise value
- $57.89B
- P/E (TTM)
- 69.2 10-yr median 26.0
- Forward P/E
- 12.5
- PEG ratio
- 0.71
- Price / sales
- 2.8 10-yr median 0.8
- Price / book
- 5.8 10-yr median 1.1
- EV / EBITDA
- 18.4 10-yr median 12.5
- Dividend yield
- —
- Beta
- 0.82
TEVA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTEVA valuation Price multiples at each fiscal year-end price.
TEVA returns How much profit the business earns on the capital it uses.
TEVA per-share figures Results divided by the shares outstanding at year-end.
TEVA financial health Debt, liquidity and how easily interest is covered.
TEVA efficiency & capital use Working capital cycle and where the cash goes.
TEVA valuation history
TEVA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TEVA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TEVA cash returned to shareholders
TEVA price vs earnings per share
TEVA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $36.61B | $24.93B | $11.68B | $10.12B | $8.87B | $10.57B | $10.69B | $15.74B | $19.25B | $34.84B |
| Enterprise value | $50.44B | $39.71B | $28.61B | $28.88B | $30.16B | $34.79B | $36.06B | $42.88B | $50.77B | $69.65B |
| P/E ratio | 26.0 | — | — | — | 21.3 | — | — | — | — | 105.9 |
| Price / sales | 2.1 | 1.5 | 0.7 | 0.7 | 0.6 | 0.6 | 0.6 | 0.8 | 0.9 | 1.6 |
| Price / book | 4.6 | 4.6 | 1.6 | 1.3 | 0.9 | 1.1 | 0.8 | 1.1 | 1.1 | 1.0 |
| Price / free cash flow | 31.9 | 33.3 | 13.9 | 9.7 | 37.6 | 16.6 | 25.5 | 8.8 | 7.3 | 8.1 |
| Price / operating cash flow | 22.2 | 20.0 | 8.5 | 6.4 | 11.1 | 8.7 | 19.9 | 6.4 | 5.5 | 6.7 |
| EV / sales | 2.9 | 2.4 | 1.8 | 1.9 | 1.9 | 2.1 | 2.1 | 2.3 | 2.3 | 3.2 |
| EV / EBITDA | 16.1 | 9.0 | 66.1 | — | 6.8 | 7.5 | 8.1 | 230.5 | — | 24.0 |
| EV / free cash flow | 43.9 | 53.0 | 34.0 | 27.7 | 127.8 | 54.5 | 86.1 | 23.9 | 19.3 | 16.1 |
| Earnings yield | 3.9% | −6.6% | −4.8% | −24.2% | 4.7% | −37.8% | −9.3% | −13.7% | −84.5% | 0.9% |
| Free cash flow yield | 3.1% | 3.0% | 7.2% | 10.3% | 2.7% | 6.0% | 3.9% | 11.4% | 13.7% | 12.4% |
| Dividend yield | — | — | — | — | — | — | 0.5% | 0.1% | 6.0% | 4.5% |
| Shareholder yield (dividends + buybacks) | — | — | — | — | — | — | 19.0% | 11.5% | 6.0% | 4.5% |
| Share price at fiscal year-end | $31.21 | $22.04 | $10.44 | $9.12 | $8.01 | $9.65 | $9.80 | $15.42 | $18.95 | $36.25 |
| Per share | ||||||||||
| Revenue per share | $14.71 | $14.63 | $14.16 | $13.45 | $14.34 | $15.21 | $15.48 | $18.47 | $22.03 | $22.79 |
| Earnings per share | $1.20 | −$1.45 | −$0.50 | −$2.20 | $0.38 | −$3.64 | −$0.92 | −$2.11 | −$16.01 | $0.34 |
| Operating cash flow per share | $1.41 | $1.10 | $1.22 | $1.43 | $0.72 | $1.11 | $0.49 | $2.40 | $3.45 | $5.44 |
| Free cash flow per share | $0.98 | $0.66 | $0.75 | $0.94 | $0.21 | $0.58 | $0.38 | $1.76 | $2.59 | $4.50 |
| Cash per share | $3.03 | $2.92 | $2.88 | $2.52 | $1.96 | $1.99 | $1.81 | $1.75 | $0.95 | $1.03 |
| Book value per share | $6.74 | $4.75 | $6.71 | $7.03 | $9.28 | $9.16 | $12.81 | $14.40 | $17.09 | $34.69 |
| Tangible book value per share | −$10.12 | −$12.55 | −$13.46 | −$14.50 | −$15.56 | −$17.83 | −$20.26 | −$23.72 | −$28.24 | −$33.88 |
| Dividends per share | — | — | — | — | — | — | $0.05 | $0.02 | $1.14 | $1.62 |
| Capex per share | $0.43 | $0.44 | $0.47 | $0.49 | $0.51 | $0.53 | $0.11 | $0.64 | $0.86 | $0.94 |
| Debt per share | $14.82 | $15.98 | $18.01 | $19.42 | $21.19 | $24.11 | $25.06 | $28.32 | $31.96 | $37.25 |
| Shares outstanding | 1.17B | 1.13B | 1.12B | 1.11B | 1.11B | 1.09B | 1.09B | 1.02B | 1.02B | 961.0M |
| Change in shares outstanding | +3.7% | +1.1% | +0.8% | +0.3% | +1.1% | +0.4% | +6.9% | +0.5% | +5.7% | +11.2% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 21.2% | −25.5% | −7.3% | −27.1% | 4.1% | −33.3% | −7.0% | −13.4% | −64.2% | 1.0% |
| Return on invested capital (ROIC) | 10.3% | −1.1% | 1.3% | −6.0% | 3.6% | −7.7% | −0.9% | −2.9% | −23.6% | 2.1% |
| Return on assets (ROA) | 3.5% | −4.0% | −1.3% | −5.3% | 0.8% | −7.4% | −1.7% | −3.3% | −19.9% | 0.4% |
| Return on tangible assets | 6.7% | −8.3% | −2.7% | −12.2% | 2.1% | −18.9% | −4.7% | −9.9% | −66.2% | 1.2% |
| Free cash flow margin | 6.7% | 4.5% | 5.3% | 7.0% | 1.5% | 3.8% | 2.5% | 9.5% | 11.8% | 19.7% |
| Income quality (OCF / net income) | 1.17 | — | — | — | 1.91 | — | — | — | — | 15.88 |
| Financial health | ||||||||||
| Total debt | $17.38B | $18.08B | $20.15B | $21.56B | $23.46B | $26.40B | $27.34B | $28.92B | $32.48B | $35.80B |
| Cash & short-term investments | $3.56B | $3.30B | $3.23B | $2.80B | $2.17B | $2.18B | $1.98B | $1.78B | $963.0M | $988.0M |
| Net debt | $13.83B | $14.78B | $16.93B | $18.76B | $21.29B | $24.22B | $25.37B | $27.13B | $31.51B | $34.81B |
| Debt / equity | 2.20 | 3.36 | 2.68 | 2.76 | 2.28 | 2.63 | 1.96 | 1.97 | 1.87 | 1.07 |
| Debt / assets | 0.43 | 0.46 | 0.46 | 0.49 | 0.49 | 0.52 | 0.48 | 0.48 | 0.46 | 0.39 |
| Net debt / EBITDA | 4.40 | 3.34 | 39.09 | — | 4.83 | 5.25 | 5.72 | 145.88 | — | 12.02 |
| Current ratio | 1.04 | 0.98 | 1.02 | 1.05 | 1.14 | 0.99 | 0.98 | 0.96 | 0.86 | 0.92 |
| Quick ratio | 0.80 | 0.75 | 0.69 | 0.72 | 0.79 | 0.65 | 0.66 | 0.63 | 0.58 | 0.65 |
| Interest coverage | 2.4 | -0.3 | 0.4 | -2.4 | 1.9 | -4.7 | -0.5 | -1.9 | -19.5 | 1.6 |
| Working capital | $490.0M | −$244.0M | $238.0M | $582.0M | $1.55B | −$159.0M | −$210.0M | −$528.0M | −$2.54B | −$1.56B |
| Invested capital | $21.74B | $20.15B | $24.43B | $26.56B | $31.57B | $34.25B | $39.34B | $41.84B | $48.87B | $68.15B |
| Tangible asset value | −$11.87B | −$13.85B | −$14.44B | −$15.30B | −$16.26B | −$18.49B | −$21.02B | −$23.13B | −$27.31B | −$30.90B |
| Net current asset value | −$18.89B | −$21.05B | −$22.87B | −$23.36B | −$23.85B | −$26.57B | −$28.94B | −$31.09B | −$36.49B | −$40.94B |
| Graham number | $13.50 | — | — | — | $8.87 | — | — | — | — | $16.35 |
| Graham net-net per share | −$21.23 | −$23.44 | −$24.63 | −$25.16 | −$26.15 | −$29.01 | −$31.13 | −$35.63 | −$42.42 | −$50.77 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | $52.0M | $22.0M | $1.16B | $1.56B |
| Share buybacks (net) | — | — | — | — | — | — | $1.98B | $1.78B | $0 | $0 |
| Dividend payout ratio | — | — | — | — | — | — | — | — | — | 473.6% |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | 483.8% | 100.5% | 44.1% | 36.0% |
| Capex / revenue | 2.9% | 3.0% | 3.3% | 3.7% | 3.5% | 3.5% | 0.7% | 3.5% | 3.9% | 4.1% |
| Capex / operating cash flow | 30.4% | 39.9% | 38.5% | 34.5% | 70.4% | 47.5% | 22.1% | 26.6% | 24.9% | 17.2% |
| Capex / depreciation | 0.50 | 0.47 | 0.46 | 0.42 | 0.42 | 0.37 | 0.29 | 0.35 | 0.41 | 0.59 |
| Stock-based compensation / revenue | 0.9% | 0.7% | 0.8% | 0.8% | 0.7% | 0.8% | 0.1% | 0.8% | 0.6% | 0.6% |
| R&D / revenue | 5.9% | 6.4% | 6.0% | 5.6% | 6.9% | 10.8% | 6.0% | 6.4% | 8.3% | 9.6% |
| SG&A / revenue | 23.0% | 22.4% | 22.1% | 23.1% | 22.2% | 22.0% | 22.5% | 22.4% | 22.3% | 23.3% |
| Efficiency | ||||||||||
| Days sales outstanding | 71.6 | 71.3 | 81.8 | 100.6 | 104.7 | 112.4 | 124.3 | 125.4 | 119.4 | 107.3 |
| Days of inventory on hand | 135.7 | 151.2 | 174.8 | 175.6 | 181.1 | 180.3 | 178.6 | 166.9 | 155.9 | 162.1 |
| Days payables outstanding | 103.8 | 103.4 | 99.9 | 82.0 | 75.8 | 71.0 | 69.7 | 67.8 | 66.7 | 74.0 |
| Cash conversion cycle (days) | 103.4 | 119.2 | 156.7 | 194.2 | 210.0 | 221.7 | 233.2 | 224.4 | 208.7 | 195.3 |
| Receivables turnover | 5.10 | 5.12 | 4.46 | 3.63 | 3.49 | 3.25 | 2.94 | 2.91 | 3.06 | 3.40 |
| Payables turnover | 3.52 | 3.53 | 3.65 | 4.45 | 4.81 | 5.14 | 5.24 | 5.38 | 5.47 | 4.93 |
| Inventory turnover | 2.69 | 2.41 | 2.09 | 2.08 | 2.02 | 2.02 | 2.04 | 2.19 | 2.34 | 2.25 |
| Asset turnover | 0.43 | 0.40 | 0.36 | 0.33 | 0.32 | 0.31 | 0.29 | 0.29 | 0.27 | 0.30 |
| Average receivables | $3.38B | $3.23B | $3.55B | $4.11B | $4.55B | $5.13B | $5.75B | $6.47B | $7.33B | $6.44B |
| Average payables | $2.37B | $2.40B | $2.24B | $1.79B | $1.72B | $1.74B | $1.79B | $1.96B | $2.11B | $2.04B |
| Average inventory | $3.09B | $3.51B | $3.93B | $3.83B | $4.11B | $4.41B | $4.58B | $4.83B | $4.94B | $4.46B |
| Intangibles / total assets | 48.5% | 49.8% | 51.9% | 54.3% | 57.7% | 58.3% | 62.8% | 64.1% | 65.2% | 70.9% |
Computed from TEVA's annual financial statements (latest annual report filed February 3, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TEVA valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Teva Pharmaceutical Industries traded at 26.0 times earnings, against a 10-year median of 26.0. Based on the latest twelve months, the trailing P/E is 69.2 and the forward P/E is 12.5. Teva Pharmaceutical Industries earned a return on equity of 21.2% and a return on invested capital of 10.3% in fiscal 2025. It ended the year with $17.4 billion of debt and $3.6 billion in cash and short-term investments, net debt of $13.8 billion. The share count rose 22.1% from 961.0M to 1.17B over 9 years.
See the TEVA income statement, the TEVA chart for price history, or the TEVA stock overview for the latest quote and news.
TEVA key metrics FAQ
What is Teva Pharmaceutical Industries's P/E ratio?
Teva Pharmaceutical Industries's trailing P/E ratio is 69.2 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 12.5. At the end of fiscal 2025 it was 26.0, compared with a 10-year median of 26.0.
What is Teva Pharmaceutical Industries's EV/EBITDA?
Teva Pharmaceutical Industries's enterprise value was 16.1 times EBITDA at the end of fiscal 2025 (enterprise value $50.4 billion, EBITDA $3.1 billion); the current EV/EBITDA is 18.4.
What is Teva Pharmaceutical Industries's return on equity?
Teva Pharmaceutical Industries's return on equity (ROE) was 21.2% in fiscal 2025: net income of $1.4 billion on average shareholders' equity of $6.6 billion.
What is Teva Pharmaceutical Industries's ROIC?
Teva Pharmaceutical Industries's return on invested capital was 10.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Teva Pharmaceutical Industries have?
Teva Pharmaceutical Industries had total debt of $17.4 billion at the end of fiscal 2025, a debt-to-equity ratio of 2.20 and $13.8 billion of net debt (4.40 times EBITDA).
What is Teva Pharmaceutical Industries's free cash flow yield?
Teva Pharmaceutical Industries generated $1.1 billion of free cash flow in fiscal 2025, a free cash flow yield of 3.1% on its market value at year-end ($36.6 billion).
What is Teva Pharmaceutical Industries's current ratio?
Teva Pharmaceutical Industries's current ratio was 1.04 at the end of fiscal 2025: current assets were 1.04 times current liabilities.